Evidence map›Paper›PMID 29860981›Full record

ArticleTrends in cancer2018

Nanoinformatics Revolutionizes Personalized Cancer Therapy.

Tamar Sadan, David P Cormode, Rachela Popovtzer

Abstract readComment
PubMed Publisher
In one paragraph

Article in Trends in cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Nanotechnology-Based Histone Deacetylase Inhibitors for Cancer Therapy.Frontiers in cell and developmental biology · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Tamar SadanFaculty of Engineering and the Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan 5290002, Israel.
David P CormodeDepartment of Radiology, University of Pennsylvania, Philadelphia, PA, USA.
Rachela PopovtzerFaculty of Engineering and the Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan 5290002, Israel. Electronic address: rachela.popovtzer@biu.ac.il.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Designing personalized cancer nanomedicines is a challenging process. The emerging field of nanoinformatics can facilitate this process by enabling computational design of nanocarrier-encapsulated drugs. Recent data show that quantitative structure-nanoparticle assembly calculations predict particle formation and size, and can lead to safer and more effective personalized cancer therapeutics.

Indexed as

NanomedicineNeoplasmsHumansNanoparticlescaveolin-mediated endocytosismachine learningnanoinformaticsnanomedicinetyrosine kinase inhibitors

Identifiers

PMID29860981

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.